a1862d
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued:
15 February 2024, London UK
GSK completes acquisition of Aiolos Bio
GSK plc
(LSE/NYSE: GSK) today announced that it has completed the
acquisition of Aiolos Bio (Aiolos), a clinical-stage
biopharmaceutical company focused on addressing the unmet treatment
needs of patients with respiratory and inflammatory
conditions.
As
previously announced,[1] the
acquisition of Aiolos includes AIO-001, a potentially
best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP)
monoclonal antibody ready to enter phase II clinical development
for the treatment of adult patients with asthma. AIO-001 could
expand GSK's respiratory biologics portfolio to potentially reach
the 40% of severe asthma patients with low T2 inflammation (a type
of overactive immune response associated with asthma).[2] AIO-001 has
the potential to be administered every six months due to its high
potency and long half-life, which could redefine the
standard-of-care.
Tony Wood, Chief Scientific Officer, GSK, said: "Given the limited treatment options for asthma
patients with low T2 inflammation, we look forward to using our
deep respiratory expertise to potentially offer a long-acting
biologic to a broader portion of the 315 million patients living
with asthma."
GSK has
an industry-leading portfolio of marketed and investigational
medicines to address a range of respiratory diseases, including
biologics aimed at treating the subset of asthma patients with high
levels of eosinophils or high T2 inflammation. Adding AIO-001 could
expand GSK's portfolio to include a biologic for severe asthma
patients with low T2 inflammation.
Financial considerations
Under
the terms of the agreement, GSK will pay a $1 billion upfront
payment and up to $400 million in certain success-based regulatory
milestone payments. In addition, GSK will also be responsible for
success-based milestone payments as well as tiered royalties owed
to Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui). AIO-001 was
exclusively licensed to Aiolos for development and
commercialisation rights outside of Greater China by
Hengrui.
About AIO-001
AIO-001
is a novel monoclonal antibody with the potential for longer dosing
intervals, such as every six months, due to its half-life and
potency. AIO-001 binds to the human thymic stromal lymphopoietin
(TSLP) ligand to inhibit TSLP signalling. TSLP has a validated,
central role in driving inflammation in asthma.
About GSK in respiratory
For
more than 50 years, GSK has led the way in developing medicines
that advance the management of respiratory conditions, from
introducing the world's first selective short-acting beta agonist
in 1969 to launching 13 respiratory medicines and six vaccines to
create today's industry-leading respiratory portfolio. We are
investing in innovative science to transform patient outcomes in
existing and new respiratory disease areas and are pushing the
frontiers of respiratory science to improve the lives of millions
of patients living with respiratory conditions.
About GSK
GSK is
a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
Camilla
Campbell
|
+44 (0)
7803 050238
|
(London)
|
|
Steph
Mountifield
|
+44 (0)
7796 707505
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q4 Results for 2023.
Registered
in England & Wales:
No.
3888792
Registered
Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
References
[1] GSK
enters agreement to acquire Aiolos Bio | GSK -
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-aiolos-bio/
[2] Albers FC, Müllerová H, Gunsoy NB, et
al. Biologic treatment eligibility for real-world patients with
severe asthma: The IDEAL study. J Asthma. 2018;55(2):152-160.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: February
15, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|